COVID-19-Influenza Combo Vaccine Candidate Featured at World Vaccine Congress

As the COVID-19 pandemic wanes, upcoming vaccination campaigns will focus on consumer choice in selecting updated vaccines. As of April 2, 2024, the World Health Organization has Listed 13 COVID-19 vaccines.

On April 3, Novavax, Inc. will host a panel discussion, "The Future of COVID-19 Vaccinations," featuring Dr. Robert Walker, the Chief Medical Officer.

This innovative discussion will explore the advantages of creating broadly protective antigens or combination vaccines.

It will showcase continued progress on data from Novavax's updated protein-based COVID-19 vaccine (NVX-CoV2601) with its Matrix-M™ adjuvant and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC.

New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant and for the currently circulating JN.1 subvariant. Data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).

Additionally, Novavax will discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial, which is anticipated to start in the second half of 2024.

COVID-19 vaccines and flu shots are offered at most pharmacies in the U.S.

Furthermore, adults without health insurance and adults whose health insurance does not cover all COVID-19 vaccine costs at an in-network provider can get updated COVID-19 vaccines at a pharmacy for free through the U.S. CDC's Bridge Access Program.